108 related articles for article (PubMed ID: 18618487)
1. Structural modifications of salicylates: inhibitors of human CD81-receptor HCV-E2 interaction.
Holzer M; Ziegler S; Neugebauer A; Kronenberger B; Klein CD; Hartmann RW
Arch Pharm (Weinheim); 2008 Aug; 341(8):478-84. PubMed ID: 18618487
[TBL] [Abstract][Full Text] [Related]
2. Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2.
Drummer HE; Wilson KA; Poumbourios P
Biochem Biophys Res Commun; 2005 Mar; 328(1):251-7. PubMed ID: 15670777
[TBL] [Abstract][Full Text] [Related]
3. Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction: synthesis and structure optimization.
Holzer M; Ziegler S; Albrecht B; Kronenberger B; Kaul A; Bartenschlager R; Kattner L; Klein CD; Hartmann RW
Molecules; 2008 May; 13(5):1081-110. PubMed ID: 18560330
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of 1-boraadamantaneamine derivatives with selective astrocyte vs C6 glioma antiproliferative activity. A novel class of anti-hepatitis C agents with potential to bind CD81.
Wagner CE; Mohler ML; Kang GS; Miller DD; Geisert EE; Chang YA; Fleischer EB; Shea KJ
J Med Chem; 2003 Jul; 46(14):2823-33. PubMed ID: 12825926
[TBL] [Abstract][Full Text] [Related]
5. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.
Drummer HE; Boo I; Maerz AL; Poumbourios P
J Virol; 2006 Aug; 80(16):7844-53. PubMed ID: 16873241
[TBL] [Abstract][Full Text] [Related]
6. Interaction of hepatitis C virus envelope glycoprotein E2 with the large extracellular loop of tupaia CD81.
Tian ZF; Shen H; Fu XH; Chen YC; Blum HE; Baumert TF; Zhao XP
World J Gastroenterol; 2009 Jan; 15(2):240-4. PubMed ID: 19132776
[TBL] [Abstract][Full Text] [Related]
7. Kinetics of HCV envelope proteins' interaction with CD81 large extracellular loop.
Nakajima H; Cocquerel L; Kiyokawa N; Fujimoto J; Levy S
Biochem Biophys Res Commun; 2005 Mar; 328(4):1091-100. PubMed ID: 15707989
[TBL] [Abstract][Full Text] [Related]
8. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor.
Masciopinto F; Campagnoli S; Abrignani S; Uematsu Y; Pileri P
Virus Res; 2001 Nov; 80(1-2):1-10. PubMed ID: 11597743
[TBL] [Abstract][Full Text] [Related]
9. Protein-dynamics of the putative HCV receptor CD81 large extracellular loop.
Neugebauer A; Klein CD; Hartmann RW
Bioorg Med Chem Lett; 2004 Apr; 14(7):1765-9. PubMed ID: 15026067
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors.
Ziegler S; Kronenberger B; Albrecht BA; Kaul A; Gamer AL; Klein CD; Hartmann RW
J Biomol Screen; 2009 Jul; 14(6):620-6. PubMed ID: 19531666
[TBL] [Abstract][Full Text] [Related]
11. The GBV-C envelope glycoprotein E2 does not interact specifically with CD81.
Kaufman TM; McLinden JH; Xiang J; Engel AM; Stapleton JT
AIDS; 2007 May; 21(8):1045-8. PubMed ID: 17457101
[TBL] [Abstract][Full Text] [Related]
12. Tellimagrandin I, HCV invasion inhibitor from Rosae Rugosae Flos.
Tamura S; Yang GM; Yasueda N; Matsuura Y; Komoda Y; Murakami N
Bioorg Med Chem Lett; 2010 Mar; 20(5):1598-600. PubMed ID: 20144544
[TBL] [Abstract][Full Text] [Related]
13. Identification of ligands that target the HCV-E2 binding site on CD81.
Olaby RA; Azzazy HM; Harris R; Chromy B; Vielmetter J; Balhorn R
J Comput Aided Mol Des; 2013 Apr; 27(4):337-46. PubMed ID: 23612915
[TBL] [Abstract][Full Text] [Related]
14. Microwave-Assisted Syntheses of Amino Acid Ester Substituted Benzoic Acid Amides: Potential Inhibitors of Human CD81-Receptor HCV-E2 Interaction.
Holzer M; Ziegler S; Kronenberger B; Klein CD; Hartmann RW
Open Med Chem J; 2008 Apr; 2():21-5. PubMed ID: 19662141
[TBL] [Abstract][Full Text] [Related]
15. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.
Higginbottom A; Quinn ER; Kuo CC; Flint M; Wilson LH; Bianchi E; Nicosia A; Monk PN; McKeating JA; Levy S
J Virol; 2000 Apr; 74(8):3642-9. PubMed ID: 10729140
[TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.
McCaffrey K; Boo I; Poumbourios P; Drummer HE
J Virol; 2007 Sep; 81(17):9584-90. PubMed ID: 17581991
[TBL] [Abstract][Full Text] [Related]
17. Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81.
Drummer HE; Wilson KA; Poumbourios P
J Virol; 2002 Nov; 76(21):11143-7. PubMed ID: 12368358
[TBL] [Abstract][Full Text] [Related]
18. [Structural biology of human CD81, a receptor for hepatitis C virus].
Kitadokoro K
Uirusu; 2004 Jun; 54(1):39-47. PubMed ID: 15449903
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus (HCV): a review of immunological aspects.
Irshad M; Khushboo I; Singh S; Singh S
Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353
[TBL] [Abstract][Full Text] [Related]
20. Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach.
Goudreau N; Cameron DR; Déziel R; Haché B; Jakalian A; Malenfant E; Naud J; Ogilvie WW; O'meara J; White PW; Yoakim C
Bioorg Med Chem; 2007 Apr; 15(7):2690-700. PubMed ID: 17306550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
